Live Earnings Conference Call: Ginkgo Bioworks will host a live Q2 2025 earnings call on August 7, 2025 at 5:30PM ET. Follow this link to get details and listen to Ginkgo Bioworks' Q2 2025 earnings call when it goes live. Get details. Ginkgo Bioworks (DNA) Competitors $13.95 -0.33 (-2.31%) Closing price 08/6/2025 03:59 PM EasternExtended Trading$13.90 -0.05 (-0.39%) As of 04:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNA vs. TWST, HCM, ALVO, KYMR, IMVT, MOR, CRNX, NAMS, GMTX, and RAREShould you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include Twist Bioscience (TWST), HUTCHMED (HCM), Alvotech (ALVO), Kymera Therapeutics (KYMR), Immunovant (IMVT), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), NewAmsterdam Pharma (NAMS), Gemini Therapeutics (GMTX), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry. Ginkgo Bioworks vs. Its Competitors Twist Bioscience HUTCHMED Alvotech Kymera Therapeutics Immunovant MorphoSys Crinetics Pharmaceuticals NewAmsterdam Pharma Gemini Therapeutics Ultragenyx Pharmaceutical Twist Bioscience (NASDAQ:TWST) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations. Which has higher earnings and valuation, TWST or DNA? Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTwist Bioscience$312.97M4.96-$208.73M-$3.25-7.97Ginkgo Bioworks$227.04M3.60-$547.03M-$9.16-1.52 Does the media refer more to TWST or DNA? In the previous week, Twist Bioscience had 13 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 20 mentions for Twist Bioscience and 7 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.65 beat Twist Bioscience's score of 0.52 indicating that Ginkgo Bioworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 5 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Ginkgo Bioworks 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in TWST or DNA? 78.6% of Ginkgo Bioworks shares are held by institutional investors. 3.0% of Twist Bioscience shares are held by company insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is TWST or DNA more profitable? Twist Bioscience has a net margin of -23.51% compared to Ginkgo Bioworks' net margin of -198.84%. Twist Bioscience's return on equity of -29.03% beat Ginkgo Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets Twist Bioscience-23.51% -29.03% -21.77% Ginkgo Bioworks -198.84%-52.35%-27.14% Do analysts prefer TWST or DNA? Twist Bioscience presently has a consensus price target of $49.40, indicating a potential upside of 90.73%. Ginkgo Bioworks has a consensus price target of $8.50, indicating a potential downside of 39.07%. Given Twist Bioscience's stronger consensus rating and higher probable upside, research analysts clearly believe Twist Bioscience is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Twist Bioscience 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73Ginkgo Bioworks 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, TWST or DNA? Twist Bioscience has a beta of 2.36, meaning that its stock price is 136% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. SummaryTwist Bioscience beats Ginkgo Bioworks on 12 of the 16 factors compared between the two stocks. Get Ginkgo Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNA vs. The Competition Export to ExcelMetricGinkgo BioworksMED IndustryMedical SectorNYSE ExchangeMarket Cap$835.84M$3.01B$5.57B$20.65BDividend YieldN/A2.41%4.31%3.66%P/E Ratio-1.5216.5729.4329.27Price / Sales3.60314.07443.8862.24Price / CashN/A42.1735.8423.31Price / Book1.067.818.084.37Net Income-$547.03M-$54.52M$3.26B$996.36M7 Day Performance6.46%0.41%0.44%0.59%1 Month Performance22.58%9.93%4.82%0.23%1 Year PerformanceN/A15.18%30.19%16.71% Ginkgo Bioworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNAGinkgo Bioworks1.0392 of 5 stars$13.95-2.3%$8.50-39.1%N/A$835.84M$227.04M-1.52640TWSTTwist Bioscience3.4567 of 5 stars$36.53+1.5%$50.40+38.0%-44.0%$2.19B$312.97M-11.24990Earnings ReportAnalyst ForecastHCMHUTCHMED3.2587 of 5 stars$17.98+2.1%$23.50+30.7%-11.4%$3.14B$630.20M0.001,811Positive NewsALVOAlvotech3.1851 of 5 stars$9.81+2.1%$14.00+42.7%-23.9%$2.96B$491.98M26.511,032KYMRKymera Therapeutics3.4848 of 5 stars$44.20-3.5%$59.11+33.7%-0.2%$2.88B$47.07M-14.26170Positive NewsIMVTImmunovant1.5548 of 5 stars$16.76-1.1%$36.30+116.6%-42.7%$2.87BN/A-6.12120MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730CRNXCrinetics Pharmaceuticals3.3486 of 5 stars$30.30-2.2%$69.50+129.4%-43.2%$2.84B$1.04M-7.93210Positive NewsNAMSNewAmsterdam Pharma3.4731 of 5 stars$23.42-0.8%$41.30+76.3%+45.5%$2.63B$45.56M-12.464News CoveragePositive NewsEarnings ReportGMTXGemini TherapeuticsN/A$60.61+0.0%N/A+45.3%$2.63BN/A-60.6130News CoverageRAREUltragenyx Pharmaceutical4.4967 of 5 stars$27.61+1.0%$82.57+199.1%-43.6%$2.61B$590.69M-4.701,294Trending NewsEarnings ReportAnalyst Forecast Related Companies and Tools Related Companies Twist Bioscience Competitors HUTCHMED Competitors Alvotech Competitors Kymera Therapeutics Competitors Immunovant Competitors MorphoSys Competitors Crinetics Pharmaceuticals Competitors NewAmsterdam Pharma Competitors Gemini Therapeutics Competitors Ultragenyx Pharmaceutical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:DNA) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNA Stock Alerts